We are a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. Currently available therapies for these diseases are limited, with many diseases having no approved therapies or treatments.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships Alzheimer's Clinical Trial Consortium (ACTC): collaboration on START trial; NIA grant funding ~$171M cumulative across programs ($81M START, $30.5M SHINE, $29.5M SHIMMER)
Indications
Alzheimer's disease(Phase 2)
Dementia with Lewy bodies (DLB) psychosis(Phase 2)
Geographic atrophy secondary to dry AMD(Phase 2)
Status note Lead product candidate. SHINE Phase 2 (mild-to-moderate AD) topline reported 2024; end-of-Phase 2 FDA meeting Jul 2025 concurred with Phase 3 plan (100 mg daily, >=6 months, low p-tau217 enrichment); START Phase 2 (545 MCI/early AD) enrollment concluded Dec 2025, topline after 18-month treatment completion. SHIMMER Phase 2 (DLB) topline Dec 2024; FDA aligned May 2026 on key aspects of pivotal DLB psychosis study (100 mg daily, 9 months). MAGNIFY Phase 2 in geographic atrophy voluntarily concluded Jan 2025 (~100 enrolled) to conserve resources.
Per-asset detail extracted from the 10-Q filed 2026-08-07. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.